Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
25 results
D2.351 - Relapse Rate and Risk Factors After Omalizumab Treatment in Adolescents with Chronic Spontaneous Urticaria
D2.352 - Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria
D2.353 - A Single Dose of Briquilimab, An Anti-Human CD117 (c-Kit) Antibody, Protects Against Relapse of Epicutaneous Allergen-Induced Dermatitis in Mice Expressing Chimeric Human/Mouse CD117
D2.354 - Questionnaire survey of new treatments for atopic dermatitis
D2.355 - Concurrent use of dupilumab and omalizumab in severe atopic dermatitis and severe chronic urticaria
D2.356 - Real-life effectiveness of omalizumab and its impact on quality of life in patients with chronic spontaneous urticaria
D2.357 - Characterizing chronic histaminergic angioedema and chronic urticaria with angioedema, a multicenter Italian experience
D2.358 - Immune shift toward the IL-17 pathway: A case of paradoxical psoriasis in a patient with severe atopic dermatitis induced by dupilumab
D2.359 - Safety and effectiveness of Omalizumab for Cold Urticaria in pediatric age
D2.362 - Dual biological therapy with dupilumab and ixekizumab in a patient with asthma, nasal polyposis, atopic dermatitis and psoriasis
D2.363 - Lanadelumab Effect on Hereditary Angioedema Activity Score: A Tertiary Center Experience
D2.364 - Omalizumab Use in Pediatric Chronic Urticaria, A Retrospective Study from a Tertiary Hospital
D3.399 - Age-Dependent Manifestations of Eosinophilic Gastrointestinal Disorders Beyond Eosinophilic esophagitis
D3.402 - Potential role of Advanced Glycation End-products in Pediatric Eosinophilic Esophagitis
D3.403 - Dupilumab improves multiple histopathologic features of eosinophilic esophagitis over 52 weeks: Post hoc analysis of the phase 3 LIBERTY EoE TREET study
D3.404 - Disease induction in a mouse model of eosinophilic esophagitis is lymphocyte dependent
D3.405 - Clinical Characteristics and Treatment Response of Eosinophilic Esophagitis in Pediatric Patients: A Descriptive Study from a High-Complexity Colombian Institution
D3.406 - Experience of dupilumab in difficult-to-treat eosinophilic esophagitis - A Case Series of 6 Portuguese Patients
D3.407 - Clinic-pathological characteristics and comorbidities in adult patients with eosinophilic esophagitis in Greece
D3.409 - Eosinophilic esophagitis and hen's egg tolerance: two cases highlighting remission with strongly heated but not less heated hen's egg despite topical steroid treatment
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download